Galvus- A New Oral Medication For Type 2 Diabetics Is Receiving Warm Reviews
A new oral medicine that is indicated for type 2 diabetics has gained positive reviews. Galvis is to be used in conjunction with the most common diabetic medications.
Novartis has received a positive opinion recommending European Union approval of Galvus® (vildagliptin) as a new once-daily oral medication for type 2 diabetes, a disease affecting an estimated 28 million patients in Europe
This approval came the same day that the CHMP recommended approval for two other Novartis medicines, Aclasta® (zoledronic acid 5 mg) for postmenopausal osteoporosis and Exelon® (rivastigmine transdermal patch) for Alzheimer’s disease. It was a good day for the fellows over at Novartis, yeah?
Just how does Galvus work in ones body?
As a member of the new class of DPP-4 inhibitors, Galvus works through a novel mechanism of action by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes. Islet dysfunction, along with insulin resistance, is a contributory factor to type 2 diabetes, a progressive disease in which control of blood sugar deteriorates over time.
Do you have all that? Januvia is another medicine in this same classification of DPP-4 inhibitors. And if you want to read what I had to say, or ramble on about, as many of y’all have come to understand, check my post out here.
via ACN Newswire
Tags: Diabetes Management, diabetics, drug, galvus, januvia, jsp, novartis, novartus, oral_medicine, pharma, type1-2Related Stories
POSTED IN: Uncategorized
0 opinions for Galvus- A New Oral Medication For Type 2 Diabetics Is Receiving Warm Reviews
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: